CC-11050: Clinical Trials

2 completed, 2 unknown. 3 Phase 2, 1 Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	3	Unknown 2, Completed 1
Phase 1	1	Completed 1

Follow CC-11050: new trials by email Literature Review of CC-11050 trials Research Report on CC-11050

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study to Evaluate the Safety, Tolerability Pharmacokinetics, and Pharmacodynamics of a New Spray Dried Dispersion (SDD) Formulation of CC-11050 After Single Dose of CC-11050 and to Evaluate the Pharmacokinetics of CC-11050 Under Fasted and Fed Conditions and After Coadministration With Omeprazole CC-11050 - Healthy Volunteers	Phase 1	Completed	Amgen	44	2019-08-28	2020-06-22
CC-11050 Trial in Nepalese Patients With Erythema Nodosum Leprosum CC-11050 - Erythema Nodosum Leprosum, Leprosy	Phase 2	Unknown	The Leprosy Mission Nepal	50	2018-01-07	2020-07-07
TB Host Directed Therapy Everolimus 0.5 MG, Auranofin 6 MG, Vitamin D3 - Tuberculosis	Phase 2	Unknown	The Aurum Institute NPC	200	2016-11-01	2019-01-10
To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus CC-11050, Placebo - Cutaneous Lupus Erythematosus	Phase 2	Completed	Amgen	48	2010-10-01	2020-06-23

Conditions studied

Leprosy (1)  ·  Lupus Erythematosus, Cutaneous (1)  ·  Lupus Erythematosus, Discoid (1)  ·  Tuberculosis (1)

Sponsors

Amgen (2)  ·  The Aurum Institute NPC (1)  ·  The Leprosy Mission Nepal (1)

Countries

United States (2)  ·  Nepal (1)  ·  South Africa (1)

Top investigators

Mahesh Shah, MD (1)  ·  Robert S Wallis, MD,FIDSA (1)

Results publications

PMID 33740465, PMID 42308518